DFCI Logo
DFCI Logo

CAR T-Cell Therapy for Lymphoma

    In this section

    Adult CAR T-Cell Therapy

    877-801-2278
    df_bcc_pos_rgb.png

    Pediatric CAR T-Cell Therapy

    617-632-5064

    Dana-Farber/Boston Children's is a certified treatment center for providing the recently FDA-approved CAR T-cell therapy called KYMRIAH® to patients who are up to 25 years old with second or later relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).

    df_boston_pos_rgb.png
    caron-jacobson-at-computer653x447.jpg
    Caron Jacobson, MD, is involved in clinical trials of CAR T-cell therapies for patients with a type of lymphoma.

     

    CAR T-cell therapy is a promising treatment for some patients with non-Hodgkin lymphoma (NHL) that has relapsed or has not responded to other therapies (refractory). It is a highly-specialized therapy that involves genetically modifying a patient's own T cells to attack their cancer. The FDA has approved several CAR T-cell therapies for lymphoma. Dana-Farber Brigham Cancer Center is one of the first centers to make the FDA-approved CAR T-cell therapies available as standard of care to patients who have not had effective treatment options. CAR T-cell therapies are FDA approved for:

    • Aggressive relapsed or refractory large B-cell lymphoma including diffuse large B cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, high-grade B-cell lymphoma, and transformed follicular lymphoma.
    • Relapsed or refractory mantle cell lymphoma
    • Relapsed or refractory follicular lymphoma

    Our program also offers patients clinical trials of CAR T-cell therapy for other forms of lymphoma as well as trials of CAR T-cell therapy earlier in treatment and in combination with other immunotherapies.

    Patients are evaluated carefully to determine if this therapy is appropriate for them. Learn more about CAR T-cell therapy.
     

    Key Eligibility Criteria for CAR T-Cell Therapy for Lymphoma

    Patients who meet the following eligibility criteria may be appropriate for CAR T-cell therapy:

    • Confirmed diagnosis of DLBCL, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, or transformed follicular lymphoma to DLBCL that has relapsed or not responded to at least two prior lines of systemic therapy, if the initial response to first-line therapy was longer than 12 months.
      • Patients with these diagnoses who do not achieve remission or relapse within 12 months of first-line therapy are eligible for CAR T as a second-line therapy.
      • Patients with DLBCL that has relapsed or not responded to first-line treatment and are not eligible for stem cell transplant are eligible for CAR T as a second-line therapy.
    • Confirmed diagnosis of follicular lymphoma that has relapsed or not responded after two prior lines of treatment.
    • Confirmed diagnosis of mantle cell lymphoma that has either not responded to, or relapsed after first line of therapy

    Related Links

    CAR T-cell therapy helps runner zoom past follicular lymphoma

    Video: FDA-approved CAR T-cell therapy for follicular lymphoma

    CAR T-Cell Therapy Gives Patients New Hope

    CAR T-Cell Therapy for Lymphoma: What You Need to Know

    Facebook Live: CAR T-Cell Therapy and Lymphoma

    Caron Jacobson, MD, Medical Director of the Immune Effector Cell Therapy program, discussed the first approval of chimeric antigen receptor (CAR) T-cell therapy for certain patients with non-Hodgkin lymphoma in October 2017.

    CAR T-cell therapy approved for mantle cell lymphoma

    Caron Jacobson, MD, detailed the research that led to FDA approval of CAR T-cell therapy for mantle cell lymphoma in July 2020.